3,614 Shares in IQVIA Holdings Inc. $IQV Purchased by Tulsa Wealth Advisors INC

Tulsa Wealth Advisors INC acquired a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) during the 2nd quarter, HoldingsChannel reports. The institutional investor acquired 3,614 shares of the medical research company’s stock, valued at approximately $698,000.

Other hedge funds also recently bought and sold shares of the company. Boston Partners purchased a new position in shares of IQVIA in the third quarter worth approximately $676,698,000. Norges Bank acquired a new stake in shares of IQVIA during the fourth quarter valued at approximately $497,445,000. Victory Capital Management Inc. lifted its position in shares of IQVIA by 2,628.1% in the 4th quarter. Victory Capital Management Inc. now owns 1,675,479 shares of the medical research company’s stock valued at $377,670,000 after acquiring an additional 1,614,063 shares in the last quarter. Orbis Allan Gray Ltd boosted its stake in IQVIA by 96.5% in the 4th quarter. Orbis Allan Gray Ltd now owns 1,901,091 shares of the medical research company’s stock worth $428,525,000 after purchasing an additional 933,554 shares during the period. Finally, Bank of New York Mellon Corp acquired a new position in IQVIA in the 2nd quarter worth approximately $180,296,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

IQV has been the topic of several recent analyst reports. Mizuho boosted their target price on shares of IQVIA from $215.00 to $230.00 and gave the company an “outperform” rating in a research note on Monday, July 13th. William Blair raised IQVIA to a “strong-buy” rating in a research report on Tuesday, July 28th. HSBC reiterated a “buy” rating and set a $240.00 price target on shares of IQVIA in a report on Monday, July 6th. Wall Street Zen raised IQVIA from a “hold” rating to a “buy” rating in a research note on Saturday, August 1st. Finally, Deutsche Bank Aktiengesellschaft set a $240.00 price objective on IQVIA in a research report on Thursday, July 9th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $241.88.

IQVIA Trading Down 0.2%

Shares of NYSE:IQV opened at $236.18 on Monday. The firm has a fifty day moving average of $206.65 and a two-hundred day moving average of $186.72. The company has a quick ratio of 0.71, a current ratio of 0.71 and a debt-to-equity ratio of 2.18. IQVIA Holdings Inc. has a 12-month low of $154.50 and a 12-month high of $251.36. The firm has a market capitalization of $38.87 billion, a P/E ratio of 29.30, a price-to-earnings-growth ratio of 2.01 and a beta of 1.18.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, topping analysts’ consensus estimates of $3.03 by $0.12. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The business had revenue of $4.37 billion for the quarter, compared to the consensus estimate of $4.30 billion. During the same period in the prior year, the business posted $2.81 earnings per share. IQVIA’s revenue for the quarter was up 8.7% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, equities analysts expect that IQVIA Holdings Inc. will post 11.57 EPS for the current fiscal year.

IQVIA declared that its Board of Directors has approved a stock buyback program on Thursday, May 7th that allows the company to buyback $2.00 billion in outstanding shares. This buyback authorization allows the medical research company to reacquire up to 6.8% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s leadership believes its stock is undervalued.

Insider Transactions at IQVIA

In related news, insider Keriann Cherofsky sold 558 shares of the stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total value of $136,827.18. Following the transaction, the insider owned 2,989 shares in the company, valued at approximately $732,932.69. This represents a 15.73% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Bhavik Patel sold 1,855 shares of IQVIA stock in a transaction that occurred on Friday, July 31st. The shares were sold at an average price of $235.27, for a total transaction of $436,425.85. Following the completion of the sale, the insider owned 1,348 shares of the company’s stock, valued at $317,143.96. This trade represents a 57.91% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 12,913 shares of company stock worth $3,098,793. 1.70% of the stock is owned by company insiders.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.